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Abstract Mitochondrial permeability transition (MPT) and
cytochrome c redistribution from mitochondria are two events
associated with apoptosis. We investigated whether an MPT
event obligatorily leads to cytochrome c release in vivo. We have
previously shown that treatment of human osteosarcoma cells
with the protonophore m-chlorophenylhydrazone (CCCP) for 6 h
induces MPT and mitochondrial swelling without significant cell
death. Here we demonstrate that release of cytochrome c does
not occur and the cells remain viable even after 72 h of treatment
with CCCP. Bax is not mobilized to mitochondria under these
conditions. However, subsequent exposure of CCCP-treated cells
to etoposide or staurosporine for 48 h results in rapid cell death
and cytochrome c release that is accompanied by Bax association
with mitochondria, demonstrating competency of these mito-
chondria to release cytochrome c with additional triggers. Our
findings suggest that MPT is not a sufficient condition, in itself,
to effect cytochrome c release. ß 2001 Federation of European
Biochemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Mitochondria play a pivotal role in apoptosis [1,2]. Two
mitochondrial events that are proposed to mediate this con-
trol of apoptosis are the mitochondrial permeability transition
(MPT) and release of pro-apoptotic proteins from the inter-
membrane space of mitochondria.
MPT is characterized by an abrupt increase in the perme-
ability of the inner mitochondrial membrane to solutes with
molecular mass below 1.5 kDa. This has been attributed to
the opening of a mitochondrial megachannel, the MPT pore,
proposed to be located at contact sites between the inner and
outer mitochondrial membranes [3]. Pore opening inevitably
leads to the dissipation of the mitochondrial membrane po-
tential (v8m), chemical equilibration of solutes across the
membranes and, as studied in isolated mitochondria, large
amplitude swelling of the mitochondrial matrix with conse-
quent loss of outer membrane integrity [4,5]. The role of
MPT in cell death is supported by pharmacological interven-
tions in which the use of MPT inducers (e.g. atractyloside)
promote apoptotic changes [6,7] whilst MPT inhibitors (e.g.
bongkrekic acid) attenuate onset of apoptosis [6,8].
The translocation of pro-apoptotic proteins from the mito-
chondrial intermembrane space into the cytosol is another key
event, which leads to the activation of caspases. The best
studied of these apoptogenic proteins is cytochrome c, which
upon translocation into the cytosol, forms a multimeric com-
plex with Apaf-1, the mammalian homologue of the death
initiating protein CED-4 of Caenorhabditis elegans [9], in an
ATP-requiring reaction. This complex is able to recruit pro-
caspase-9 and activate it. In turn, caspase-9 can proteolyti-
cally cleave downstream caspases, such as caspase-3, to exe-
cute the biochemical and morphological features of apoptosis
[10,11]. The role of cytochrome c as a mediator of mitochon-
dria-dependent caspase activation and cell death is supported
by in vivo studies involving microinjection of cytochrome c
into intact cells [12,13], and in vitro studies using cell-free
systems [14].
How cytochrome c is released from the mitochondria is not
fully understood [15]. One hypothesis is that MPT may pre-
cipitate this outcome. This is based, ¢rst, on ¢ndings that
isolated mitochondria undergoing an MPT-dependent swell-
ing release intermembrane space proteins including cyto-
chrome c [16,17]. Second, in apoptotic cells, cytochrome c
redistribution from mitochondria is preceded by, or occurs
concurrently with, depolarization of v8m [8,18^20]. However,
not all the data available support this model. In particular,
there has been inconsistency in the results obtained for v8m
changes associated with cytochrome c release. In some apo-
ptotic cell systems, v8m loss was observed only after cyto-
chrome c e¥ux [21^23] whilst in others, an absence of change
in v8m was observed [24,25]. In addition, some studies on the
pro-apoptotic Bcl-2 family member, Bax, have demonstrated
that cytochrome c could be released independently of an MPT
event [26,27]. This has led to proposed alternative models
involving a speci¢c release mechanism via a Bax-regulated
channel [2,15].
In this study, we have investigated whether MPT and cyto-
chrome c release are obligatorily connected events, particu-
larly testing the hypothesis that MPT in vivo leads to cyto-
chrome c release. We have previously reported that treatment
of human osteosarcoma cells (an immortal adherent cell line)
with the protonophore carbonyl cyanide m-chlorophenylhy-
drazone (CCCP) resulted in MPT events. The mitochondria
in such CCCP-treated cells showed loss of v8m and morpho-
logical swelling [28]. Signi¢cantly, mitochondria preloaded in
vivo with calcein (Mr 623) released this marker dye upon
treatment of cells with CCCP; this release was inhibited by
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cyclosporin A [28], thus con¢rming the response as an authen-
tic MPT [4] in intact cells. Here, we report that MPT induced
by CCCP-mediated mitochondrial depolarization in osteosar-
coma cells does not lead to cytochrome c release or cell death,
even after extended periods of treatment (up to 72 h), indicat-
ing that MPT, as such, is not a su⁄cient condition for cyto-
chrome c release in vivo.
2. Materials and methods
2.1. Reagents
CCCP, staurosporine, and etoposide were purchased from Sigma
(St. Louis, MO, USA). Monoclonal mouse anti-cytochrome c and
anti-Bax IgGs were from Pharmingen (San Diego, CA, USA), goat
anti-mouse IgG conjugated to £uorescein isothiocyanate (FITC) was
from Biosource International (Camarillo, CA, USA), and goat anti-
mouse IgG conjugated to Alexa 568 and rhodamine-123 (Rh123) were
from Molecular Probes (Eugene, OR, USA).
2.2. Cell culture
Human osteosarcoma cells 143B TK3 were cultured as previously
described [28]. A derivative of this cell line stably expressing mito-
chondrially targeted green £uorescent protein (mtGFP) was also gen-
erated. A recombinant plasmid pCZ34 [29], expressing GFP5 fused at
its N-terminus to the 16 amino acid mitochondrial targeting sequence
of human 3-oxoacyl-CoA thiolase (hOACTL), was transfected into
osteosarcoma cells using Lipofectamine Plus (Gibco BRL). Brie£y,
1 Wg plasmid was pre-complexed with the Plus and Lipofectamine
reagents, and then incubated with the cells in serum-free and anti-
biotic-free culture medium for 3 h at 37‡C. At 48 h post transfection,
cells containing the expressed plasmid were selected by adding G418
(A.G. Scienti¢c, CA, USA) at a ¢nal concentration of 600 Wg/ml. The
cells were monitored for 1 week with medium change every 2^3 days,
maintaining selection. The surviving cells were harvested and seeded
at 100 cells per 100 mm culture dish to allow colony formation. The
colonies were analysed for GFP expression and one colony (denoted
B4) was selected for use in this study.
2.3. Treatment of cells
Cells were seeded at a density of 1U105 into six-well plates the day
before treatment. One group of cells was treated with either 10 WM
CCCP, 100 WM etoposide or 100 nM staurosporine alone whilst an-
other group of cells was initially treated with 10 WM CCCP for 6 h
and subsequently treated with either etoposide or staurosporine.
2.3. Immunocytochemical staining of cytochrome c and Bax
For each treatment group, a portion of cell suspension containing
viable (adherent) and non-viable (detached) cells was placed onto
glass slides coated with poly-L-lysine (0.01%) by centrifugation at
1000 rpm for 5 min using a Cytospin (Shandon Scienti¢c, UK). Cells
were ¢xed with 3.5% paraformaldehyde (PFA) for 10^15 min, per-
meabilized with 0.1% Triton X-100 for 10 min, and incubated for 1.5^
2 h with either monoclonal anti-cytochrome c or anti-Bax primary
antibody (diluted 1/50) and then for 1 h with secondary antibody
(diluted 1/100) conjugated either with FITC or Alexa 568. Coverslips
were mounted onto glass slides with Fluoroguard anti-fade reagent
(Bio-Rad Laboratories, CA, USA) and sealed with clear nail polish.
Cells were either scored for release/non-release of cytochrome c or
cytosolic/mitochondrial localization of Bax in situ following visual-
ization with a Leica TCS-NT upright confocal microscope using a
63U oil immersion objective.
2.5. Cell viability
Trypan blue exclusion was performed in order to assess viability of
cells. Following incubation with the appropriate reagent(s) for 24, 48
and 72 h, detached and adherent fractions were collected separately,
and each fraction was stained with 0.2% trypan blue. Viable (trypan
blue-negative) and non-viable (trypan blue-positive) cells were
counted using a haemocytometer under a light microscope.
2.6. Monitoring v8m
Loss of v8m as a result of CCCP treatment was monitored by
Rh123 staining. Cells were incubated with 10 WM Rh123 for 15 min
at 37‡C and then washed three times with culture medium. Images of
Rh123 stained cells incubated with and without CCCP were obtained
with a Leica TCS-NT inverted confocal microscope. For each group,
images of at least 10 ¢elds of cells (with each ¢eld containing v100
cells) were taken using a 16U oil/water immersion objective lens. Both
£uorescence and phase contrast images were obtained and subse-
quently merged for quanti¢cation of £uorescence intensity using an
MCID image analysis software (Imaging Research Inc., Canada). The
total number of pixels per unit area of cell was quanti¢ed and ad-
justed for background. The mean pixel value was then calculated per
image and the mean of the mean was obtained for each group.
2.7. Statistical analysis
Statistical analysis was performed using the unpaired Student’s
t-test to compare the results in experimental and control groups of
cells.
3. Results
3.1. MPT and loss of v8m induced by CCCP do not lead to
cytochrome c release or cell death
Intact osteosarcoma cells treated with CCCP were previ-
ously observed to undergo MPT and mitochondrial swelling
in the absence of cell death. We further investigated whether
CCCP-induced MPT under these conditions led to the release
of cytochrome c from mitochondria. In brief, cells were
treated with CCCP for a period of 72 h and total cell pop-
ulation (viable+non-viable) was collected every 24 h and im-
munostained for cytochrome c. Visualization of FITC £uores-
cence revealed two types of population of cells. One typically
showed a mitochondrially compartmentalized pattern of £uo-
rescence (Fig. 1A), which was categorized as negative for cy-
tochrome c release; the other showed clearly di¡used £uores-
cence including coverage of the nuclear region (Fig. 1B),
which was designated positive for cytochrome c release.
Examination of cells after CCCP treatment revealed that at
all time points tested (24, 48, and 72 h) about 1^3% of cells
had released cytochrome c, comparable to that of untreated
cells (0.4^2%) (data not shown in detail here, but see also Fig.
3A below). The small percentage of cells positive for cyto-
chrome c release in the untreated group is attributed to the
spontaneous release of cytochrome c associated with a sto-
chastic (and as yet uncharacterized) activation of the death
mechanism in these cells. The lack of release in the CCCP-
treated cells is paralleled by the minimal loss in cell viability
such that greater than 95% of cells remained viable even after
72 h of treatment, as also observed in untreated controls (data
Fig. 1. Distribution of cytochrome c in situ. Immunocytochemical
staining for cytochrome c revealed two types of cells : those showing
no release of cytochrome c (A) or those showing release of cyto-
chrome c (B). Scale bars indicate 10 Wm.
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not shown in detail here, but see also Fig. 3B below). These
cells also did not stain with either annexin V or propidium
iodide, indicating that they are not apoptotic.
To con¢rm that v8m remained dissipated under these ex-
tended conditions of CCCP treatment, cells were stained with
Rh123, a reporter dye which accumulates in a Nernstian man-
ner in mitochondria and is thus sensitive to changes in inner
membrane potential. Rh123 £uorescence was monitored every
24 h for 72 h by confocal microscopy. For both untreated and
CCCP-treated groups, the mean £uorescence intensity was
determined and loss of Rh123 £uorescence in CCCP-treated
cells was expressed as percentage of untreated control. As
shown in Fig. 2, the Rh123 £uorescence was reduced by ap-
prox. 80% at all time points, indicating that the mitochondria
in CCCP-treated cells were continuously depolarized during
the course of treatment.
3.2. Additional treatment of CCCP-treated cells with etoposide
or staurosporine causes release of cytochrome c with
concomitant cell death
In order to determine whether cytochrome c could be re-
leased from mitochondria of CCCP-treated cells, having
undergone MPT, the cells were further treated with the apo-
ptotic inducers etoposide or staurosporine. Cells were pre-
treated with CCCP for 6 h during which time MPT has oc-
curred and were then subsequently treated with either
Fig. 2. Cells treated with CCCP for extended periods maintain loss
of v8m. A: Representative images of cells stained with Rh123,
without (a) or with (b) CCCP treatment for 48 h. For comparison
of £uorescence intensity, the £uorescence gain level was ¢rst cali-
brated for untreated control where there is intense mitochondrial
Rh123 £uorescence (indicative of high vim) and CCCP-treated cells
were imaged using the same photomultiplier gain level. Scale bars
indicate 20 Wm. B: Quantitative analysis of Rh123 £uorescence in
CCCP-treated cells relative to untreated control. Rh123 £uorescence
in CCCP-treated cells was expressed as a percentage of that in un-
treated control, which was designated to have 100% £uorescence.
Fig. 3. E¡ects of etoposide and staurosporine treatment on cyto-
chrome c release and cell viability. A: Percentage of cells that have
released cytochrome c out of the total cells counted in untreated,
CCCP, etoposide (etp), CCCP plus etoposide, staurosporine (sts),
and CCCP plus staurosporine groups. B: Cell viability of the vari-
ous treatment groups, determined by trypan blue exclusion. Treat-
ment times were 24 h (black bars) and 48 h (shaded bars). Symbols
in A and B indicate signi¢cant di¡erences between the CCCP-
treated reference group and either CCCP plus etoposide-treated
cells, or CCCP plus staurosporine-treated cells, for both time points
(*P6 0.1; #P6 0.05).
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etoposide or staurosporine for 24, 48 and 72 h whilst main-
taining CCCP in the medium. A cell population analysis was
carried out after the appropriate time of incubation, involving
cytochrome c immunocytochemistry and determination of cell
viability.
Etoposide or staurosporine treatment alone did not cause
release of cytochrome c in a signi¢cant proportion of cells
(6 50%) after 24 h (Fig. 3A). By 48 h, however, the propor-
tion of cells showing cytochrome c release had increased to
near maximal levels (about 90%), associated with an increase
in the percentage of non-viable cells to greater than 85% by
that time (Fig. 3B). Prior treatment of cells with CCCP did
not signi¢cantly a¡ect this outcome, suggesting that the mech-
anism enabling cytochrome c release is functional in CCCP-
treated cells upon exogenous induction of apoptosis.
3.3. The release of cytochrome c is accompanied by Bax
localization into mitochondria
Movement of Bax from the cytosol into mitochondria has
been reported to facilitate the release of cytochrome c follow-
ing apoptotic induction [30,31]. We have therefore monitored
localization of endogenous Bax in cells subjected to the di¡er-
ent treatment regimes. Mitochondrial £uorescence was visual-
ized in osteosarcoma cells expressing mitochondrially targeted
GFP (mtGFP) and Bax was detected by indirect immuno-
staining using a secondary antibody conjugated to Alexa
568, a red £uorophore. Confocal microscopy of untreated
B4 cells showed di¡used Bax immunoreactivity encompassing
most cell regions, including the cytosol, but excluding the
nucleoli (Fig. 4A1). This was also the case in CCCP-treated
cells, consistent with their failure to release cytochrome c (Fig.
4A2). However, cells treated with etoposide (Fig. 4A3) or stau-
rosporine (Fig. 4A4) showed a more punctate distribution of
Bax, the vast majority of which co-localizes well with mtGFP.
These data clearly demonstrate translocation of Bax from the
cytosol to mitochondria under these conditions of apoptotic
induction.
The proportion of cells showing mitochondrial localization
of Bax was quanti¢ed in the same manner as for cytochrome c
and the results are depicted in Fig. 4B. CCCP treatment alone
did not cause any signi¢cant change in Bax distribution such
that 99% of cells showed cytosolic Bax staining after 48 h of
treatment. In contrast, approx. 40% and 50% of cells treated
with etoposide or staurosporine, respectively, showed mito-
chondrial Bax distribution at that time. CCCP pretreatment
did not have any signi¢cant e¡ect on the values obtained for
both these conditions of apoptotic induction. Thus, the results
correlate with the cytochrome c release data, although the
C
Fig. 4. Bax distribution following CCCP, etoposide or staurosporine
treatment. A: Representative images of cells showing (a) mtGFP-la-
belled mitochondria (green emission channel) and (b) Bax immuno-
staining (red emission channel). Panel 1, untreated cells. Panels 2, 3
and 4, cells treated for 48 h with CCCP, etoposide and staurospo-
rine, respectively. Scale bars indicate 10 Wm. Note that in untreated
cells, the mitochondria no longer appear ¢lamentous (cf. Fig. 2A)
due to trypsinization and centrifugation in this experiment. B: Per-
centage of cells showing mitochondrial localization of Bax out of
the total cells counted for the various treatment groups. Treatment
times were 24 h (black bars) and 48 h (shaded bars). Symbols indi-
cate signi¢cant di¡erences between the reference group of cells
treated with CCCP only and those treated with CCCP plus another
agent (#P6 0.05).
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absolute proportions quanti¢ed were generally lower for Bax
compared with cytochrome c. In particular, the proportion of
cells showing mitochondrial Bax following etoposide or stau-
rosporine treatment for 48 h did not exceed 50% whilst great-
er than 90% of these cells showed release of cytochrome c. We
therefore cannot exclude that cytochrome c may be released
via a Bax-independent pathway in these cells.
4. Discussion
4.1. Occurrence of MPT without cytochrome c release in vivo
It has been proposed that MPT can induce apoptosis via
the release of cytochrome c and other pro-apoptotic proteins
from the intermembrane space due to MPT-mediated swelling
of mitochondria and subsequent permeabilization of the outer
membrane. This proposal is based primarily on studies in
vitro whereby induction of MPT in isolated mitochondria
directly causes swelling with concomitant non-speci¢c release
of intermembrane space proteins [17,18]. In this study, we
tested whether this situation actually applies in vivo, in intact
cells.
Our approach to monitoring MPT in intact cells entails use
of the £uorescent dye calcein, whose £uorescence in mito-
chondria is speci¢cally revealed when cytosolic calcein £uo-
rescence is quenched with cobalt (Co2) [28,32]. We have ob-
served that treatment of human osteosarcoma cells with
CCCP not only causes dissipation of v8m as its primary ac-
tion but also induces pore opening within 30 min, as visual-
ized by the release of mitochondrially entrapped calcein [28].
This calcein release was signi¢cantly inhibited by the addition
of cyclosporin A (a known MPT inhibitor [4]) validating our
inference that a genuine MPT has taken place. This MPT was
maintained for a period of up to 6 h during which time no
apparent cellular damage was observed and was also accom-
panied by mitochondrial swelling judged by confocal micros-
copy [28].
We have extended this line of investigation to determine
whether CCCP-induced MPT eventually leads to cytochrome
c e¥ux from mitochondria in these osteosarcoma cells. Anal-
ysis of cytochrome c distribution by immuno£uorescence in
conjunction with confocal microscopy showed that there was
no signi¢cant di¡erence in the CCCP-treated cells compared
to the untreated control even after extended periods of treat-
ment. This demonstrates that an MPT event coupled with
prolonged disruption of the proton gradient by CCCP does
not facilitate release of cytochrome c. Thus, MPT and cyto-
chrome c release are not mutually exclusive events in this in
vivo system.
4.2. Response of mitochondria to additional triggers: possible
role of Bax
Cytochrome c redistribution in CCCP-treated cells did oc-
cur, however, following additional treatment with either eto-
poside or staurosporine for 48 h, and this was concomitant
with cell death. This suggests that the mitochondria are still
responsive to signals conveyed by extramitochondrial changes
brought about by etoposide (DNA topoisomerase II inhibitor)
or staurosporine (protein kinase inhibitor). CCCP-treated de-
polarized mitochondria thus remain as integral components of
the apoptotic machinery despite disruption in their bioener-
getic integrity. The lack of e¡ect of CCCP pretreatment on the
rate and degree of cytochrome c release in etoposide-treated
or staurosporine-treated cells further suggests that MPT is not
a prerequisite for cytochrome c redistribution. Instead, it is
likely that additional e¡ector molecules are recruited into mi-
tochondria during chemical-induced apoptosis to promote cy-
tochrome c e¥ux. Such molecules may include the pro-apo-
ptotic member of the Bcl-2 family, Bax, which is known to
translocate from the cytosol into mitochondria where it oli-
gomerizes and forms large conductance channels in the outer
membrane [33,34].
Previous studies in vivo have shown that treatment of var-
ious mammalian cells with etoposide or staurosporine causes
mobilization of Bax to mitochondria, which in turn e¡ects
release of cytochrome c [35,36]. The residence of Bax in cells
not induced apoptotically includes various cytoplasmic loca-
tions as well as the nucleus [36,37]. CCCP by itself had no
e¡ect on the distribution of Bax, suggesting that cytochrome c
release in osteosarcoma cells may require stimulus such as Bax
localization to mitochondria. Indeed, additional incubation
with either etoposide or staurosporine for 48 h revealed Bax
to localize in the mitochondria in a signi¢cant proportion of
cells, and this, in general, paralleled cytochrome c release.
This suggests that Bax translocation into mitochondria was
involved in the release of cytochrome c. However, it may not
be the sole mechanism governing this event. In only about
half of the cells in which release of cytochrome c occurred,
was there observed mitochondrially localized Bax, and this
was obtained for both etoposide and staurosporine treat-
ments. Thus, there may be other signalling factors, such as
other pro-apoptotic members of the Bcl-2 family and caspases
[38,39], that may e¡ect release of cytochrome c in this system.
Nevertheless, our data suggest that MPT pore opening and
loss of v8m are not su⁄cient for the translocation of cyto-
chrome c from mitochondria in vivo. The additional partici-
pation of Bax and possibly of other signalling molecules, ei-
ther in conjunction with or independently of MPT, is required
to activate cytochrome c release.
4.3. Di¡erences in mitochondrial behaviour in vivo and in vitro
The absence of cytochrome c release following MPT de-
tected here contrasts with that observed in vitro, and suggests
that a di¡erent mechanism of release may occur in intact cells.
In particular, one may consider that a more speci¢c mode of
release via an outer membrane channel could be favoured in
vivo rather than a non-speci¢c mode of release due to rupture
of the outer membrane. Some authors [2,15] have reported
that mitochondria do not swell but become condensed before
cytochrome c release. However, MPT with consequent mito-
chondrial swelling cannot be altogether excluded as a possible
mechanism for the release of cytochrome c in certain individ-
ual cell types subjected to particular treatments. In rat thy-
mocytes for instance, induction of MPT has been shown to
lead to cytochrome c redistribution and cell death [18]. Sim-
ilarly, mitochondrial swelling detected by electron microscopy
in Jurkat T cells undergoing Fas-induced or staurosporine-
induced apoptosis preceded release of cytochrome c [40,41].
Although we have observed swelling as a result of CCCP-
induced MPT in osteosarcoma cells by confocal microscopy,
it is possible that the degree of swelling achieved was insu⁄-
cient to cause breakage of the outer membrane. We obtained
similar observations to those reported here, following treat-
ment of osteosarcoma cells with valinomycin, a K ionophore
that also collapses vim and induces MPT. Under these con-
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ditions, there was marked swelling of mitochondria that was
more profound than that observed in CCCP-treated cells but,
again, cytochrome c was not released (M.L.R. Lim and P.
Nagley, unpublished data). In these situations of MPT and
swelling in vivo, the absence of cytochrome c release following
MPT is likely to be due to the outer membrane remaining
intact. It can be postulated that the process of mitochondrial
swelling in vivo di¡ers from that occurring in isolated mito-
chondria such that the degree of swelling may be subjected to
a more tight regulation. Bcl-XL, an anti-apoptotic Bcl-2 pro-
tein localized in the mitochondrial outer membrane, has been
shown to play a role in maintaining osmotic homeostasis of
mitochondria [40]. The presence of this protein may therefore
restrict the extent of swelling of mitochondria in intact cells,
which may also vary amongst di¡erent cell types.
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